MiCareo — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $2.8M

Overview

MiCareo is a private, commercial-stage diagnostics company specializing in advanced liquid biopsy systems for rare cell analysis. Its core technology platform, centered on the ensemble-decision aliquot ranking (eDAR) method, enables the automated capture and multiplexed imaging of live circulating tumor cells and immune cells with high purity. The company offers two main product systems: the MiSelect R II for cell isolation and the MiCount for AI-driven cell detection, targeting applications in drug development and clinical research. MiCareo is positioned in the growing liquid biopsy market, providing tools for non-invasive, real-time monitoring of cellular-level disease dynamics.

OncologyImmunologyInfectious Disease

Technology Platform

Proprietary microfluidic platform utilizing ensemble-decision aliquot ranking (eDAR) for high-purity, live rare cell isolation, combined with automated multiplexed fluorescence imaging and AI-driven detection.

Funding History

1

Total raised:$2.8M

Seed$2.8MUndisclosedNov 15, 2021

Opportunities

The growing liquid biopsy market, particularly for therapy monitoring in oncology and immunology, presents a major opportunity.

The need for live cells for functional analysis and single-cell sequencing in drug development creates strong demand for MiCareo's high-purity isolation technology.

The upcoming launch of the lower-cost MiCount system could significantly expand its customer base to include more academic and smaller biotech labs.

Risk Factors

Key risks include intense competition from established and emerging liquid biopsy companies, the challenge of driving adoption and displacing entrenched research methods, and dependence on the cyclical R&D spending of pharmaceutical and academic customers.

Any future move into the clinical diagnostics space would introduce significant regulatory and reimbursement hurdles.

Competitive Landscape

MiCareo competes in the rare cell analysis segment of the liquid biopsy market against companies like Menarini Silicon Biosystems (CellSearch, DEPArray), Fluxion Biosciences, and BioFluidica. It differentiates through its eDAR technology's combination of high purity, live cell output, and automation. Broader competition includes ctDNA-focused liquid biopsy firms (e.g., Guardant Health, Freenome) and traditional flow cytometry providers, though these offer complementary or different types of cellular information.

More companies in Diagnostics & Precision Medicine →More companies in United States →